<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Classic" granulomatosis with polyangiitis (GPA) is a form of systemic vasculitis (polyangiitis) with necrotizing granulomatous inflammation of the upper and lower respiratory tracts, systemic necrotizing vasculitis, and necrotizing glomerulonephritis [
         <a href="#rid1">
          1,2
         </a>
         ]. Microscopic polyangiitis (MPA) is a necrotizing vasculitis without granulomatous inflammation that predominantly affects small vessels (ie, capillaries, venules, or arterioles) and can present with pulmonary capillaritis or in the context of interstitial lung disease [
         <a href="#rid3">
          3
         </a>
         ]. Both MPA and GPA are considered ANCA-associated vasculitides, although ANCA testing may be negative in some patients.
        </p>
        <p>
         The major features of respiratory tract involvement in GPA and MPA will be reviewed here. Issues related to the approach to and management of systemic vasculitides, as well as the pathogenesis, clinical manifestations, diagnosis, therapy, and outcomes in GPA and MPA are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8224.html" rel="external">
          "Overview of the management of vasculitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3074.html" rel="external">
          "Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with granulomatosis with polyangiitis (GPA) typically have both upper airway and pulmonary involvement, although a minority may have just one or the other [
         <a href="#rid1">
          1
         </a>
         ]. Nonspecific complaints of fever, anorexia, weight loss, and malaise are often present [
         <a href="#rid4">
          4,5
         </a>
         ]. Microscopic polyangiitis (MPA) affecting the respiratory tract is most often associated with alveolar hemorrhage [
         <a href="#rid6">
          6,7
         </a>
         ]. The clinical manifestations of GPA and MPA outside the respiratory tract are discussed separately.
        </p>
        <p>
         In the past, the term "limited" GPA was used to describe patients with clinical findings isolated to the upper respiratory tract or lungs, which occurs in approximately one-fourth of cases. The term was confusing, as "limited" disease could be severe. The current practice is to describe the locations of organ involvement and the severity of disease at each location. Thus, a patient can have "severe" disease in the lungs in the presence of antineutrophil cytoplasmic antibody (ANCA)-associated diffuse alveolar hemorrhage with mild extrapulmonary involvement [
         <a href="#rid8">
          8
         </a>
         ]. Many patients with disease limited to upper respiratory tract or lungs subsequently develop systemic involvement [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Nasal, sinus, and ear disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with GPA, approximately 90 percent have nasal, sinus, or ear involvement, compared with 35 percent of patients with MPA, who have sensorineural hearing loss [
         <a href="#rid10">
          10-12
         </a>
         ]. Nasal, sinus, and ear involvement may be present without other disease manifestations for weeks to months before progressing to more generalized, "vasculitic" disease.
        </p>
        <p>
         The most common presenting symptoms and signs of GPA or MPA related to the nares, sinuses, and ears include the following [
         <a href="#rid1">
          1,13-18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal crusting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sinus pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic rhinosinusitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal obstruction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smell disturbances
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Purulent/bloody nasal discharge
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive tearing (ie, epiphora)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Formation of sinus mucoceles (benign, epithelium-lined cysts filled with mucus)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conductive and/or sensorineural hearing loss
        </p>
        <p>
        </p>
        <p>
         Patients often present with symptoms of nasal congestion and purulent nasal discharge suggestive of a sinus infection that has failed to resolve with appropriate antibiotic therapy. Chronic rhinosinus involvement with GPA can lead to nasal septal perforation, saddle nose deformity, serous otitis, hearing loss, and nasocutaneous fistulae [
         <a href="#rid13">
          13,19,20
         </a>
         ]. Nasal polyposis is not seen in GPA. Adjacent structures may also be involved (eg, orbital pseudotumor with proptosis and vision impairment, oral ulcers) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Airway and lung involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common respiratory symptoms in GPA and MPA are cough, hemoptysis (due to alveolar hemorrhage and/or tracheobronchial disease), dyspnea, and pleuritic pain. The severity of symptoms and signs varies considerably from asymptomatic (one-third of patients) to acute and fulminant alveolar hemorrhage with respiratory failure. Among patients with GPA, it is unusual for pulmonary symptoms to occur in the absence of upper respiratory tract symptoms or signs. The specific clinical manifestations vary depending on whether the patient has tracheobronchial disease, lung parenchymal nodules, interstitial lung disease, or alveolar hemorrhage.
        </p>
        <p class="headingAnchor" id="H4203770">
         <span class="h3">
          Tracheobronchial disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tracheobronchial involvement with GPA has several manifestations, including tracheal and bronchial stenosis, mass lesions (inflammatory pseudotumors), tracheobronchial malacia, and tracheoesophageal fistulae [
         <a href="#rid17">
          17,19
         </a>
         ]. Associated symptoms include dyspnea, stridor, cough, sputum production, and hemoptysis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subglottic stenosis is the most common manifestation of tracheobronchial GPA; reported frequencies vary from 8 to 50 percent [
         <a href="#rid17">
          17,22-25
         </a>
         ]. In a referral population, 22 percent of patients with GPA had subglottic stenosis [
         <a href="#rid22">
          22
         </a>
         ]. Subglottic stenosis may be the sole manifestation of GPA and may be severe enough to necessitate tracheostomy [
         <a href="#rid19">
          19,26
         </a>
         ]. Stridor is a sign of severe subglottic obstruction and requires urgent evaluation. (See
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchial ulceration and stenosis are less common than tracheal stenosis and may be asymptomatic or cause dyspnea, hemoptysis, and/or symptoms of postobstructive pneumonia. Bronchial disease is almost always associated with GPA disease elsewhere.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mass lesions in the trachea and bronchi due to GPA can ulcerate leading to hemoptysis or cause airway obstruction leading to dyspnea and postobstructive infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncommonly, bronchial involvement leads to airflow limitation or bronchiectasis, with productive cough, hemoptysis, wheezes, or crackles [
         <a href="#rid19">
          19,27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4204213">
         <span class="h3">
          Lung parenchymal nodules
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung parenchymal nodules usually do not cause symptoms, although patients often have constitutional or upper airway symptoms, as described above.
        </p>
        <p class="headingAnchor" id="H1761910734">
         <span class="h3">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various types of interstitial lung disease (ILD) can be seen in GPA, although ILD is more commonly associated with MPA [
         <a href="#rid29">
          29-32
         </a>
         ]. Sometimes, evidence of ILD precedes the appearance of systemic vasculitis [
         <a href="#rid4">
          4,29,31,33
         </a>
         ].
        </p>
        <p>
         In a series of 144 patients with MPA, fibrosing interstitial lung disease was noted in 12 percent at disease onset and 15 percent in long-term follow-up [
         <a href="#rid3">
          3
         </a>
         ]. In most of the patients with computed tomography images, the pattern was felt to resemble usual interstitial pneumonia (UIP) most closely.
        </p>
        <p>
         A retrospective study identified 204 patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and ILD, of whom 91 percent had MPA and 7 percent had GPA. The radiographic pattern (based on 2013 American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines [
         <a href="#rid34">
          34
         </a>
         ]) was consistent with UIP or possible UIP in 75 percent, nonspecific interstitial pneumonia (NSIP) in 19 percent, organizing pneumonia in 1.5 percent, and unclassifiable ILD in 10 percent [
         <a href="#rid35">
          35
         </a>
         ]. Patients did not undergo surgical biopsy for histologic confirmation. While p-ANCA positivity predominated in this cohort, patients with NSIP radiographic pattern had a higher likelihood of c-ANCA positivity (15 percent) than those with radiographic UIP or possible UIP (3.3 percent).
        </p>
        <p>
         A cross-sectional Italian national study of 95 consecutive patients (56 affected by MPA and 39 by GPA) also showed that NSIP pattern was more frequently observed in c-ANCA positive patients (61 percent of cases), while the UIP pattern was more often observed in p-ANCA positive patients (48 percent) [
         <a href="#rid36">
          36
         </a>
         ]. ILD was found at diagnosis in two-thirds of patients and was the first clinical manifestation (preceding vasculitis) in 22 percent of cases.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse alveolar hemorrhage (DAH) is a prominent and life-threatening pulmonary manifestation of ANCA-associated vasculitis (AAV) [
         <a href="#rid37">
          37-39
         </a>
         ]. It is estimated to occur in 5 to 45 percent of patients with AAV and may be the presenting finding [
         <a href="#rid40">
          40-42
         </a>
         ]. As an example, among 144 patients with MPA, 22 percent had alveolar hemorrhage at the time of presentation; it occurred subsequently in another 4 percent [
         <a href="#rid3">
          3
         </a>
         ]. DAH accompanied by glomerulonephritis is a form of pulmonary-renal syndrome [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         Patients with alveolar hemorrhage due to GPA or MPA typically present with the rapid onset of dyspnea and may also have cough, hemoptysis, anemia, and/or hypoxemia. Untreated, they may progress rapidly to respiratory failure. Associated constitutional symptoms and evidence of skin, neurologic, and renal involvement are common; nonspecific prodromal symptoms may precede presentation by days to weeks [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3919036321">
         <span class="h2">
          Pulmonary artery stenosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A few cases of proximal pulmonary artery stenosis have been reported in patients with GPA or MPA and attributed to involvement of the arterial wall [
         <a href="#rid44">
          44,45
         </a>
         ]. The patients presented with progressive dyspnea, and the diagnosis was made with computed tomographic pulmonary angiography [
         <a href="#rid45">
          45
         </a>
         ]. Pulmonary artery pressures may or may not be elevated on transthoracic Doppler echocardiography [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H90822002">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of patients with suspected upper or lower respiratory tract involvement with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) requires a combination of clinical assessment, serologic testing, pulmonary function testing, sinus and chest imaging, bronchoscopy, and tissue biopsy.
        </p>
        <p class="headingAnchor" id="H2663121205">
         <span class="h2">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The order of testing and speed with which it is performed depends in part on the pattern of symptoms and acuity of illness. However, it is important to establish a diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis expeditiously, as a prompt diagnosis allows the initiation of therapy that may be life-saving and organ-sparing. The results of initial testing, presence of extra-respiratory or co-morbid disease, and local expertise also influence the choice and order of procedures. Whenever possible, the least invasive biopsy site is selected (eg, skin, nares). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient presents with dyspnea and diffuse radiographic opacities, an expedited evaluation is necessary to enable rapid initiation of treatment. Testing includes routine laboratory tests, urinalysis, testing for ANCA, anti-glomerular basement membrane antibodies, and antinuclear antibodies  (
         <a class="graphic graphic_table graphicRef101060" href="/z/d/graphic/101060.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Laboratory tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient's condition allows, high resolution computed tomography (HRCT) is obtained to guide bronchoalveolar lavage (BAL). Urgent bronchoscopy is performed with a careful airway survey (to exclude ulcerations, stenosis, or mass) and BAL in a radiographically involved area to assess for alveolar hemorrhage, infection, or malignancy. In general, biopsy confirmation of GPA or MPA is highly desirable, but individual patients may be deemed to be poor surgical candidates for lung biopsy. As alternatives, less invasive sites may be used for tissue confirmation (eg, skin, kidney) or empiric therapy may be initiated on the basis of serologic results and BAL showing hemorrhage. (See
         <a class="local">
          'Bronchoscopy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who present with pulmonary nodules, a positive ANCA test result, and renal insufficiency, but no cutaneous manifestations, the choice between a lung or kidney biopsy is often debated. When pulmonary nodules are peripheral, we typically proceed with a video-assisted thoracoscopic lung biopsy. Transbronchial biopsies are generally not helpful due to insufficient sample size. On the other hand, a patient with progressive renal insufficiency may require a kidney biopsy to fully characterize their kidney disease and guide treatment. If the kidney biopsy shows pauci-immune glomerulonephritis, a lung biopsy may not be necessary. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If upper respiratory tract disease (eg, nasal obstruction, sinus opacification, crusting, bloody nasal discharge) is prominent and the patient does not have constitutional symptoms, the initial diagnostic evaluation usually includes testing for ANCAs and a sinus CT scan (if not already performed). A positive ANCA test result should be followed by additional laboratory testing (eg, complete blood count with differential, urinalysis, creatinine) and appropriate chest imaging studies. If sinus disease is extensive, biopsy of involved nasal or sinus tissue usually follows, but may be nondiagnostic. Further evaluation is aimed at obtaining histopathologic confirmation at another site, such as the skin, kidney, or lungs depending on the results of careful skin examination, laboratory testing, and chest imaging.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Laboratory tests
         </span>
        </p>
        <p class="headingAnchor" id="H929557">
         <span class="h3">
          Routine laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing, other than the ANCA, is generally nonspecific in GPA and MPA. Nonetheless, a complete blood count with differential, blood urea nitrogen (BUN), creatinine, and urinalysis are obtained in virtually all patients with suspected GPA or MPA. For patients with respiratory insufficiency and diffuse radiographic opacities, we also obtain liver and muscle enzymes, antiglomerular basement membrane (anti-GBM) antibodies, antinuclear antibodies (ANA), cryoglobulins, complement (C4), hepatitis serology, HIV screen, and blood cultures to assess potential vasculitic involvement of other organs and to exclude other processes in the differential diagnosis  (
         <a class="graphic graphic_table graphicRef101060" href="/z/d/graphic/101060.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
         For patients with nasal ulcerations or a saddle nose deformity, a toxicology screen for cocaine may be appropriate. The saddle nose deformity of syphilis is congenital and thus serologic testing for syphilis is not necessary in patients with acquired saddle nose deformity. (See
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Common hematologic abnormalities in GPA include a normochromic, normocytic anemia, leukocytosis, and thrombocytosis (&gt;400,000/mm
         <sup>
          3
         </sup>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Peripheral eosinophilia is uncommon in GPA and MPA. Marked elevation of the erythrocyte sedimentation rate (&gt;100 mm/hour by Westergren method) and an increase in C-reactive protein (CRP) are common, but nonspecific. A lack of elevation in sedimentation rate or CRP does not exclude GPA or MPA.
        </p>
        <p>
         The plasma creatinine and urinalysis are normal in limited GPA. In contrast, patients with classic GPA or MPA typically show a variable elevation in plasma creatinine concentration, mild to moderate proteinuria, and an active urine sediment with red cells, white cells, and red cell and other cellular casts.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Antineutrophil cytoplasmic antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         An indirect immunofluorescent assay for ANCAs is performed in any adult patient who presents with symptoms or signs suggestive of a vasculitis. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Granulomatosis with polyangiitis'
         </a>
         .)
        </p>
        <p>
         More than 90 percent of patients with active GPA or MPA and both lung and kidney involvement have ANCAs in the serum. In some circumstances (eg, nondiagnostic biopsy findings), a positive ANCA may provide the only clue to the correct diagnosis. However, in limited forms of GPA, ANCA testing may be negative. Conversely, a positive ANCA needs confirmatory testing with antigen-specific enzyme-linked immunosorbent assays (ELISAs) and (almost always) tissue histopathology.
        </p>
        <p>
         The majority of patients with GPA have autoantibodies directed against serine proteinase 3 (PR3), known as PR3-ANCA (C-ANCA), that are associated with diffuse cytoplasmic staining; a minority have autoantibodies directed against myeloperoxidase (MPO), known as MPO-ANCA (P-ANCA), that are associated with a perinuclear staining pattern. MPO-ANCA are also found in microscopic polyarteritis, pauci-immune glomerulonephritis, eosinophilic granulomatosis with polyangiitis (EGPA), and the drug-induced ANCA-associated vasculitis. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
         Confirmation of the presence of autoantibodies to PR3 or MPO by the specific ELISAs leads to substantially higher specificity and positive predictive values than the indirect immunofluorescence assay. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Solid-phase immunoassays'
         </a>
         .)
        </p>
        <p>
         The individual types of ANCA (PR3 or MPO) are often associated with particular patterns on computed tomography (CT). In a case series of 129 patients with ANCA-positive vasculitis and positive serology, 81 (63 percent) were PR3-ANCA positive and 48 (37 percent) were MPO-ANCA positive, and one patient was positive for both PR3 and MPO [
         <a href="#rid46">
          46
         </a>
         ]. On CT, PR3-ANCA was associated with central airways and nodular disease; MPO-ANCA was associated with a usual interstitial pneumonia pattern and bronchiectasis. Alveolar hemorrhage, pleural effusion, lymph node enlargement, and pulmonary venous congestion were more common in MPO-ANCA positive patients. (See
         <a class="local">
          'Computed tomography'
         </a>
         below.)
        </p>
        <p>
         ANCA-positivity during follow-up is associated with systemic relapses and may reflect ongoing GPA activity, while undetectable ANCA during the clinical course of the disease is associated with longer relapse-free survival. Unfortunately, the titers are not consistent enough to allow GPA or MPA management based on serial measurement of ANCA levels alone. (See
         <a class="medical medical_review" href="/z/d/html/3040.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease", section on 'Monitoring by the clinician'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs), including flow volume loops, are obtained in ambulatory patients with symptoms or signs of airway or lung involvement in GPA or MPA to assess the presence of airway involvement and the severity of lung function impairment. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p>
         Data regarding PFT results in GPA and MPA are limited [
         <a href="#rid1">
          1,47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most frequent abnormality is airflow obstruction and may be caused by diffuse airway involvement, focal tracheal or bronchial stenosis or lobar collapse
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced lung volumes and diffusing capacity for carbon monoxide (DLCO) are seen in interstitial lung disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced lung volumes are found when diffuse interstitial involvement is present
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The DLCO may be markedly increased in the presence of active alveolar hemorrhage, although these patients are often too dyspneic to perform PFTs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung function frequently improves following treatment, although the diffusing capacity may not return to normal
        </p>
        <p>
        </p>
        <p>
         Flow volume loop tracings may show flattening of the expiratory loop in patients with intrathoracic tracheal stenosis or flattening of the inspiratory loop in extrathoracic subglottic stenosis when the area of narrowing is still pliable or flattening of both inspiratory and expiratory loops when the airway lesion is tightly stenotic  (
         <a class="graphic graphic_figure graphicRef76811" href="/z/d/graphic/76811.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1465.html" rel="external">
          "Flow-volume loops", section on 'Abnormal inspiratory loop'
         </a>
         .)
        </p>
        <p>
         Oxygenation is initially assessed with pulse oximetry. A reduced oxygen saturation can be caused by pulmonary hemorrhage, infection, thromboembolism, or fluid overload. For patients with progressive respiratory impairment, arterial blood gas analysis is usually obtained.
        </p>
        <p class="headingAnchor" id="H90822068">
         <span class="h2">
          Imaging
         </span>
        </p>
        <p class="headingAnchor" id="H89945589">
         <span class="h3">
          Sinus computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiplanar computed tomography (MDCT) is the preferred imaging modality for evaluating chronic rhinosinusitis and suspected rhinosinus involvement by GPA or MPA in patients with nasal symptoms, facial pain/pressure, hyposmia, or anosmia [
         <a href="#rid48">
          48,49
         </a>
         ]. In addition, sinus CT is often obtained in patients with suspected GPA even in the absence of nasal or sinus complaints. In a case series of 28 patients with sinonasal GPA, the most common findings on sinus CT were mucosal thickening in the nasal cavity and paranasal sinuses in 61 and 75 percent, respectively [
         <a href="#rid48">
          48
         </a>
         ]. Other findings included bony destruction of the nasal cavity (57 percent), bony destruction of the paranasal sinuses (54 percent), subtotal sinus opacification (25 percent), and bony thickening (sclerosing osteitis) of the paranasal sinuses (18 percent). (See
         <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">
          "Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Sinus CT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chest radiograph is typically obtained in patients with respiratory symptoms or extrapulmonary features that suggest vasculitis. If a chest CT will be obtained promptly, the chest radiograph can be omitted. The vast majority of patients with GPA have an abnormal chest radiograph, although the appearance is highly variable. The radiographic findings usually include one or more of the following [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nodules that may be cavitary
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticular markings
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse hazy opacities, sometimes with an air bronchogram
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lobar or segmental atelectasis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleural opacities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hilar adenopathy (uncommon)
        </p>
        <p>
        </p>
        <p>
         No clear differences are noted between the chest radiograph manifestations of limited and classic GPA, except that alveolar hemorrhage generally occurs in the setting of systemic vasculitis (classic GPA or MPA) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Depending on the case series, the most commonly reported chest radiograph findings are nodules (20 to 90 percent) and patchy or diffuse opacities (20 to 50 percent) [
         <a href="#rid27">
          27,41,50,51
         </a>
         ]. Pulmonary nodules may be single or multiple and range in diameter from 1 to 10 cm [
         <a href="#rid52">
          52
         </a>
         ]. The nodules are typically diffuse in distribution and may be cavitary [
         <a href="#rid41">
          41,53
         </a>
         ]. Margins may be well-circumscribed or ill-defined.
        </p>
        <p>
         Focal segmental opacities and/or atelectasis can also occur, often distal to a site of endobronchial involvement (eg, stenosis or a mass) produced by the granulomatous inflammatory process. Other less common findings include pleural effusions, hilar adenopathy, spontaneous pneumothorax (induced by rupture of a subpleural cavitary nodule), and the presence of a fungus ball (eg, aspergilloma) in a cavity.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         HRCT scans of the chest are obtained in virtually all patients undergoing an evaluation for GPA or MPA and in patients with hemoptysis or an abnormal chest radiograph. Chest HRCT imaging is helpful in disclosing lesions not seen on the plain chest radiograph and in identifying previously unsuspected cavitary nodules  (
         <a class="graphic graphic_diagnosticimage graphicRef55999" href="/z/d/graphic/55999.html" rel="external">
          image 1
         </a>
         ) or central airway lesions [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Common CT findings in GPA include multiple pulmonary nodules (generally less than 10 in number)  (
         <a class="graphic graphic_diagnosticimage graphicRef80970" href="/z/d/graphic/80970.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef67766" href="/z/d/graphic/67766.html" rel="external">
          image 3
         </a>
         ) and ground glass or consolidative opacities that are patchy or diffuse (due to diffuse pulmonary hemorrhage or active vasculitis) [
         <a href="#rid43">
          43,50,53
         </a>
         ]. Nodules range in size from a few millimeters to 10 cm. Approximately 30 to 50 percent of nodules are cavitary and 17 percent are diffuse opacities [
         <a href="#rid4">
          4,50,54
         </a>
         ]. Less common findings include a reticular pattern, interlobular septal thickening, honeycombing, bronchiectasis, hilar adenopathy, and pleural effusions [
         <a href="#rid19">
          19,43,50,53
         </a>
         ].
        </p>
        <p>
         Among patients with MPA, common abnormalities on HRCT include ground glass opacities, reticular markings, interlobular septal thickening, bronchiolitis, bronchial wall thickening, and bronchiectasis [
         <a href="#rid55">
          55
         </a>
         ]. Areas of consolidation, honeycombing, nodular densities, and pleural abnormalities are less common.
        </p>
        <p>
         Chest HRCT scanning can also identify the presence of other findings that may suggest the diagnosis of vasculitis, including [
         <a href="#rid50">
          50,53,56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood vessels leading to nodules and cavities (feeding vessels)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small, peripheral, wedge-shaped densities suggesting pulmonary microinfarction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cuffing of the bronchovascular bundle in a lobar segmental and subsegmental distribution, often associated with narrowing of the bronchial lumen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enlarged, irregular, and stellate-shaped peripheral pulmonary arteries (the "vasculitis" sign) [
         <a href="#rid57">
          57
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previously unsuspected tracheal or bronchial stenosis  (
         <a class="graphic graphic_diagnosticimage graphicRef80970" href="/z/d/graphic/80970.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         When central airway obstruction due to subglottic or tracheal stenosis is suspected, MDCT scanning with two and three dimensional reconstruction can provide thin-section, high-spatial resolution images of the airway [
         <a href="#rid58">
          58
         </a>
         ]. Advantages of MDCT over axial or helical CT imaging include identification of subtle areas of narrowing and a more precise estimate of the craniocaudal extent of stenotic lesions. This technology also allows for noninvasive follow-up of airway lesions during the course of therapy. (See
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'
         </a>
         .)
        </p>
        <p>
         Certain CT findings may be associated with particular autoantibodies, as described above. (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H929969">
         <span class="h2">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common indications for bronchoscopy in patients with suspected GPA are to assess and biopsy endobronchial disease and perform BAL. BAL is performed in patients with diffuse parenchymal opacities on chest imaging to identify alveolar hemorrhage, if present, and to obtain samples for microbiologic and cytologic analysis. Transbronchial lung biopsy may identify an alternate diagnosis, but the sample size does not allow for a positive diagnosis of GPA [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         During the airway survey, careful attention is needed to identify areas of friable mucosa, ulceration, masses, or stenosis. Biopsy of endobronchial lesions may yield histopathology compatible with GPA, although the specimen size may be too small to make a definitive diagnosis of GPA [
         <a href="#rid59">
          59
         </a>
         ]. Endobronchial biopsy is, however, useful for excluding other diseases such as endobronchial malignancy, tuberculosis, or sarcoidosis.
        </p>
        <p>
         For patients with multiple pulmonary nodules, bronchoscopy with BAL is useful to evaluate for fungal or mycobacterial infection, but the nodules are usually inaccessible to transbronchial biopsy.
        </p>
        <p>
         When performing BAL to assess for alveolar hemorrhage, three sequential wedged lavages with 50 to 60 mL aliquots are performed in a single area. When alveolar hemorrhage is present, the returned lavage aliquots are progressively more hemorrhagic. Hemosiderin-laden macrophages are often identified on Prussian blue staining of cells from the BAL fluid, although this latter finding does not differentiate alveolar hemorrhage from diffuse alveolar damage. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Bronchoalveolar lavage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease", section on 'Hemorrhagic BAL'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H828941461">
         <span class="h2">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue confirmation of GPA or MPA is highly desirable, even among patients with a compatible clinical presentation and positive serology, due to the potential toxicity of treatment. The choice of a biopsy site must be individualized based on the accessibility of specific sites of disease and whether the patient would tolerate the planned procedure. (See
         <a class="local">
          'Approach'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H175807349">
         <span class="h3">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main indication for lung biopsy is the evaluation of single or multiple pulmonary nodules, particularly when extrapulmonary disease is absent or not accessible to biopsy [
         <a href="#rid60">
          60
         </a>
         ]. Even when GPA is strongly suspected (eg, positive ANCA), infection and metastatic disease affecting the lung must be fully excluded prior to initiating immunosuppressive therapy for GPA. (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p>
         Most patients with diffuse alveolar hemorrhage identified by diffuse radiographic opacities and a BAL showing hemorrhage are poor candidates for lung biopsy. Lung biopsy is generally not recommended in this setting, especially when unexplained anemia, a positive ANCA, and an elevated DLCO (&gt;150 percent predicted or an increase of more than 30 percent over baseline) are present. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Biopsy'
         </a>
         .)
        </p>
        <p>
         When ANCA-associated vasculitis is suspected in a patient with interstitial lung disease, the choice between lung or kidney biopsy must be made individually. It is often a difficult decision to obtain surgical lung biopsy in this setting. Importantly, when the lung is clinically involved, surgical lung biopsy usually provides definitive pathologic evidence.
        </p>
        <p>
         Generally, transthoracic needle biopsies, like transbronchoscopic biopsies, are too small for making a definitive diagnosis of GPA, although they may be performed to identify other processes (eg, infection, tumor) in the differential diagnosis. Instead, lung tissue is obtained via video-assisted thoracoscopic surgery or thoracotomy. The decision between these techniques depends on the location and size of nodules and radiographic opacities and also local expertise. Smaller, more peripheral nodules and diffuse disease are more amenable to a thoracoscopic approach, while larger more central lesions may require a thoracotomy. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H271578039">
         <span class="h3">
          Nasal or sinus biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasal and sinus biopsies are performed as part of the evaluation and treatment of nasal obstruction due to soft tissue masses and chronic sinusitis, even though the findings are often nonspecific [
         <a href="#rid13">
          13,15,16,61
         </a>
         ]. As an example, functional endoscopic sinus surgery is often performed for symptoms and signs of recurrent or persistent sinusitis and sinus biopsies are obtained in the course of the procedure. Areas of nasal mucosal ulceration or soft tissue mass are biopsied when present. Biopsies are also indicated when septal perforation, bony erosion, or collapse of the nasal bridge are noted [
         <a href="#rid13">
          13,15,21
         </a>
         ]. Samples are also sent for special stains and culture (eg, fungal, mycobacterial), as well as histopathology  (
         <a class="graphic graphic_table graphicRef63674" href="/z/d/graphic/63674.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Histopathology'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Surgical management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4049932093">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histopathologic findings in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) vary with the location and type of involvement in the respiratory tract and elsewhere. The histopathology of renal GPA and MPA are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic rhinosinusitis
         </strong>
         – Histopathologic examination of nasal and sinus tissue involved by GPA typically reveals extensive tissue necrosis and infiltration with a mixed population of inflammatory cells; necrotizing granulomas are occasionally present in GPA, but not MPA. Direct evidence of vasculitis is rarely seen in pathologic specimens from the upper respiratory tract [
         <a href="#rid62">
          62-65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tracheobronchial disease
         </strong>
         – Tracheobronchial GPA disease includes subglottic and lower tracheal and bronchial stenoses, tracheal and endobronchial mass lesions, and, less commonly, tracheobronchial malacia, follicular bronchiolitis, and bronchiolitis obliterans [
         <a href="#rid19">
          19,27,66
         </a>
         ]. The histopathologic findings of the various forms of bronchiolitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial lesion in tracheal and bronchial stenosis appears to be a circumferential area of friable mucosa and ulceration [
         <a href="#rid19">
          19
         </a>
         ]. Fibrotic scarring may occur during the resolution phase, and result in stenosis or, less commonly, tracheomalacia, or bronchiectasis. Biopsies of areas of airway stenosis due to GPA often reveal nonspecific inflammation typical of granulation tissue or fibrotic scarring, but rarely show vasculitis [
         <a href="#rid19">
          19,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Biopsies of tracheal and bronchial masses often show fibrinoid necrosis, microabscesses, and infiltration by epithelioid histiocytes and neutrophils without clear vasculitis [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary parenchymal nodules
         </strong>
         – The characteristic lung parenchymal lesions of GPA are firm, hemorrhagic to yellow-gray spherical nodules, ranging in size from 0.3 to 12 cm with an average size of 2.4 cm [
         <a href="#rid50">
          50
         </a>
         ]. Central necrosis, more friable than caseous, may be present, resulting in cavities in 25 to 50 percent of nodules [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         GPA is categorized as a small vessel vasculitis, but may affect arteries, arterioles, capillaries, venules, and veins. Microscopically, transmural infiltration of blood vessels with inflammatory cells is noted, associated with granulomatous inflammation in the surrounding tissue [
         <a href="#rid69">
          69
         </a>
         ]. Necrosis of the vessel walls and/or necrosis of inflammatory cells within the vessel walls may be visible. One issue in the histopathologic diagnosis of GPA is that infections (typically granulomatous) can cause vascular inflammation within areas of diffusely inflamed parenchyma and must be differentiated from GPA. The presence of vasculitis in an area of otherwise uninvolved lung tissue ensures that the vascular inflammation is not just a consequence of another inflammatory process [
         <a href="#rid62">
          62
         </a>
         ]. However, this finding is infrequent and the diagnosis of GPA does not require it. A separate finding that favors GPA over infection is necrosis of the vascular media, which is rarely noted when vascular inflammation is caused by infection. Negative special stains and cultures are also evidence against an infectious etiology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The granulomatous inflammation of GPA is characterized by palisading histiocytes that are oriented with their long axis perpendicular to the necrotic center [
         <a href="#rid62">
          62
         </a>
         ]. A few noncaseating granulomas may be present, but are not prominent. In general, the inflammatory changes associated with GPA are angiocentric, although a rare bronchocentric variant has been described [
         <a href="#rid52">
          52
         </a>
         ]. The infiltrating inflammatory cells include neutrophils, lymphocytes, multinucleated giant cells, and eosinophils, but eosinophils are generally not abundant. However, eosinophilic variants of GPA have been described. In a case series of four patients with a clinical syndrome consistent with GPA, lung biopsy findings otherwise consistent with GPA were associated with eosinophil infiltration, but not peripheral eosinophilia [
         <a href="#rid70">
          70
         </a>
         ]. In a separate case report, peripheral blood and pleural eosinophilia were associated with lung biopsy findings of classic GPA without eosinophil infiltration [
         <a href="#rid71">
          71
         </a>
         ]. Differentiation of the eosinophilic variants of GPA from eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) was based on clinical and histopathologic correlation. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Small areas of organizing pneumonia are often seen in association with small suppurative granulomas, foci of bland necrosis, multinucleated giant cells, and microabscesses [
         <a href="#rid66">
          66
         </a>
         ]. Rarely, prominent areas of organizing pneumonia are noted [
         <a href="#rid52">
          52,72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Histopathologic diagnosis of organizing pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interstitial lung disease
         </strong>
         – Typical histopathologic findings of patients with interstitial lung disease and MPA include fibrosis of the alveolar walls and interstitium and honeycombing [
         <a href="#rid73">
          73
         </a>
         ]. Vasculitis is not always demonstrable. In a series of 12 patients, vasculitis involved the pulmonary arterioles in three, the bronchial arteries in three, and capillaries in two [
         <a href="#rid74">
          74
         </a>
         ]. In a separate series of nine patients, the histopathologic pattern in six was consistent with usual interstitial pneumonitis (UIP) without evidence of alveolar hemorrhage or vasculitis; two patients had alveolar hemorrhage, but no evidence of vasculitis [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alveolar hemorrhage
         </strong>
         – Pulmonary capillaritis is the key histopathologic finding in GPA and MPA presenting with diffuse alveolar hemorrhage  (
         <a class="graphic graphic_picture graphicRef76904" href="/z/d/graphic/76904.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef56943" href="/z/d/graphic/56943.html" rel="external">
          picture 2
         </a>
         ); larger vessels are often uninvolved [
         <a href="#rid37">
          37,40
         </a>
         ]. Small punctate neutrophilic aggregates within areas of hemorrhage are a clue to the presence of capillaritis [
         <a href="#rid62">
          62
         </a>
         ]. A mixed inflammatory cell infiltrate is typically present within the interstitium and airspaces, as well as a small vessel leukocytoclastic vasculitis (ie, presence of degenerating neutrophils with formation of nuclear dust in the vessel wall)  (
         <a class="graphic graphic_diagnosticimage graphicRef66296" href="/z/d/graphic/66296.html" rel="external">
          image 4
         </a>
         ). Foamy macrophages and giant cells may be present, but granulomatous inflammation is usually minimal or absent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pulmonary capillaritis due to GPA or MPA is differentiated from that due to systemic lupus erythematosus (SLE) or antiglomerular basement membrane (anti-GBM) antibody (Goodpasture's) disease by immunostaining. Granular immune complex deposition is characteristic of SLE and linear IgG deposition along the capillary basement membrane is virtually diagnostic of anti-GBM antibody disease. Immune deposits are absent in MPA. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemosiderin-laden macrophages, identified by Prussian blue staining that reveals large clumps of hemosiderin, appear in alveoli approximately 48 hours after the onset of hemorrhage are typically noted in the alveoli [
         <a href="#rid62">
          62
         </a>
         ]. The large clumps of hemosiderin differentiate these macrophages from smoker's macrophages, which have a finely stippled pattern of iron deposition in the cytoplasm. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease", section on 'Hemorrhagic BAL'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90821912">
         <span class="h2">
          Testing for tuberculosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally perform a
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         or blood interferon-gamma release assay (IGRA) as part of the evaluation of patients with suspected GPA, as the clinical features and histopathology of GPA can be difficult to differentiate from granulomatous infections like tuberculosis. However, a positive result on either of these tests does not necessarily indicate active tuberculosis, nor does a negative test exclude active TB. Patients with latent TB infection will require anti-tuberculosis treatment when undergoing immunosuppressive therapy for GPA. (See
         <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">
          "Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3795926788">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) is established when serologic (ie, antineutrophil cytoplasmic antibody positivity with autoantibodies directed against serine proteinase 3 or myeloperoxidase) and histopathologic evidence of small vessel vasculitis with or without granulomatous inflammation are present in a patient with a compatible clinical presentation. The distinction between GPA and MPA can be difficult and is largely based on the presence or absence of necrotizing granulomatous inflammation on biopsy or radiographic surrogates thereof (lung nodules, cavities, or masses). As GPA and MPA are typically systemic processes, the diagnostic criteria include an assessment of the distribution of involvement in extrarespiratory organ systems (eg, kidneys, nervous system, skin, heart). The full diagnostic criteria for GPA and MPA are discussed separately.
        </p>
        <p>
         The diagnosis of GPA or MPA also depends on the exclusion of other diseases in the differential diagnosis, such as sarcoidosis, tuberculosis, antiglomerular basement membrane antibody syndrome, and drug-induced vasculitis, as described below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H929710">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of the upper and lower respiratory tract findings associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) is broad, but narrows considerably in the presence of a positive antineutrophil cytoplasmic antibody (ANCA), particularly when the enzyme-linked immunoassay shows specific antibodies to proteinase 3 (PR3) or myeloperoxidase (MPO). Diseases that require special consideration when evaluating a patient for possible GPA are described in the following sections. The differential diagnosis of a positive ANCA test is described separately. (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Disease associations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929781">
         <span class="h2">
          Chronic rhinosinusitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several granulomatous processes can cause a similar presentation to that of GPA sinonasal disease, including infections, eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss), sarcoidosis, extranodal NK/T cell nasal lymphoma (previously known as lethal midline granuloma), and others listed in the table  (
         <a class="graphic graphic_table graphicRef63674" href="/z/d/graphic/63674.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Differentiating features include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sinonasal disease associated with EGPA is less likely to cause septal perforation or other destructive lesions compared with GPA [
         <a href="#rid75">
          75
         </a>
         ]. Nasal polyposis, which is common in EGPA, is not seen in GPA. While mild peripheral blood eosinophilia can be seen in GPA, prominent peripheral blood eosinophilia (usually 5000 to 9000 eosinophils/microL) and prominent eosinophilic infiltration on histopathology favor EGPA. (See
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoidosis is suggested by the presence of lupus pernio or other typical cutaneous manifestations, and also numerous noncaseating granulomas on nasal or sinus biopsy. Hearing loss is more common in GPA and EGPA than in sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis"
         </a>
         and
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cocaine-induced midline destructive lesions (CIMDL) can mimic limited GPA and are associated with positive ANCA tests [
         <a href="#rid76">
          76,77
         </a>
         ]. In CIMDL the ANCA may be directed at proteinase 3, myeloperoxidase, or human neutrophil elastase [
         <a href="#rid78">
          78-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Constitutional symptoms and signs suggestive of ear, orbit, or lung involvement are rare in CIMDL and common in GPA. At least partial destruction of the inferior or middle turbinate and septal perforations are common in CIMDL, but uncommon in GPA [
         <a href="#rid82">
          82
         </a>
         ]. Histopathologically, the presence of extravascular granulomas and giant cells rules out CIMDL [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal NK/T cell nasal lymphoma (previously lethal midline granuloma) is diagnosed by the presence of extensive tissue ulceration and a diffuse and permeative lymphomatous infiltrate with atypical lymphoid cells. The immunophenotype is similar to that of natural killer T cells and Epstein Barr virus genome is virtually always present on in situ hybridization. (See
         <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type", section on 'Pathologic features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin G4 (IgG4)-related disease can cause a midline destructive lesion with nasal septal and palatal perforations that mimics GPA [
         <a href="#rid83">
          83
         </a>
         ]. Biopsy in IgG4-related disease shows lymphoplasmacytic infiltrates and storiform fibrosis without granulomas. Immunohistochemical staining shows IgG4-positive plasma cells. (See
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4203939">
         <span class="h2">
          Tracheal stenosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subglottic and lower tracheal lesions need to be differentiated from postintubation stenosis, relapsing polychondritis, tracheopathia osteoplastica, urticarial vasculitis, tracheal amyloidosis, cicatricial pemphigoid, and granulomatous infection. Postintubation stenosis is suggested by a history of intubation and the location of stenosis. Relapsing polychondritis is suggested by coexistent auricular and nasal polychondritis and characteristic findings on tracheal CT. The tracheal changes of relapsing polychondritis usually involve long continuous stretches of the tracheobronchial tree, whereas tracheobronchial lesions of GPA are usually localized and segmental [
         <a href="#rid84">
          84
         </a>
         ]. Tracheopathia osteoplastica also has characteristic CT features. GPA is differentiated from the other processes based on serologic, microbiologic, and histopathologic findings. (See
         <a class="medical medical_review" href="/z/d/html/131093.html" rel="external">
          "Presentation and diagnostic evaluation of non-life-threatening and nonmalignant subglottic and tracheal stenosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5609.html" rel="external">
          "Diagnostic evaluation of relapsing polychondritis", section on 'Computed tomography'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6984.html" rel="external">
          "Radiology of the trachea", section on 'Relapsing polychondritis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6984.html" rel="external">
          "Radiology of the trachea", section on 'Tracheobronchopathia osteochondroplastica'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6984.html" rel="external">
          "Radiology of the trachea", section on 'Pseudotumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929788">
         <span class="h2">
          Pulmonary nodules
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of multiple pulmonary nodules includes metastatic solid organ malignancy, non-Hodgkin lymphoma, septic emboli, granulomatous infections (eg,
         <em>
          Mycobacteria
         </em>
         , histoplasmosis, coccidioidomycosis, cryptococcosis, aspergillosis),
         <em>
          Paragonimus
         </em>
         infection in endemic areas, sarcoidosis, rheumatoid arthritis, lymphomatoid granulomatosis, inflammatory myofibroblastic tumor, silicosis, and coal-worker's pneumoconiosis. Differentiation is based on history of exposures, presence of other features (eg, erosive arthritis, cutaneous lesions), serology, special stains and culture, and histopathology. (See
         <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">
          "Diagnostic evaluation of the incidental pulmonary nodule"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929795">
         <span class="h2">
          Alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of alveolar hemorrhage due to GPA or MPA is broad and includes other vasculitides (eg, cryoglobulinemia, immunoglobulin A vasculitis [Henoch-Schönlein purpura], drug-induced ANCA associated vasculitis), rheumatic diseases (eg, lupus, antiphospholipid antibody syndrome, polymyositis, anti-glomerular basement membrane [GBM] antibody syndrome), anticoagulant therapy, thrombocytopenia, drug-induced lung injury, toxic exposures (eg, trimellitic anhydride), infections, acute respiratory distress syndrome, cardiac dysfunction, and pulmonary infarction  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Clues to a specific etiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'
         </a>
         .)
        </p>
        <p>
         A few medications (eg,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">
          propylthiouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ) can cause ANCA positivity, alveolar hemorrhage, and glomerulonephritis as part of a drug-induced vasculitis [
         <a href="#rid85">
          85,86
         </a>
         ]. As an example, a number of cases of hydralazine-induced alveolar hemorrhage with crescentic glomerulonephritis have been reported in association with perinuclear ANCA (P-ANCA) positivity (positive myeloperoxidase) [
         <a href="#rid87">
          87-89
         </a>
         ]. Typically, these patients also have positive antinuclear antibodies and antihistone antibodies. (See
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3853889311">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have identified an increased risk of venous thromboembolic disease among patients with GPA and other ANCA-associated vasculitides, although the cause of hypercoagulability is unclear [
         <a href="#rid90">
          90-94
         </a>
         ]. In one series, the cumulative incidence at 10 years was 4 percent for pulmonary embolism and 7 percent for deep venous thrombosis [
         <a href="#rid93">
          93
         </a>
         ]. Most of the events occurred in the first two years following diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3074.html" rel="external">
          "Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of GPA and MPA and the management of central airway obstruction and diffuse alveolar hemorrhage are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Follow-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132732.html" rel="external">
          "Management of non-life-threatening, nonmalignant subglottic and tracheal stenosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3153313843">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">
          "Society guideline links: Vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H929576">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions and major characteristics
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Granulomatosis with polyangiitis
         </strong>
         – "Classic" granulomatosis with polyangiitis (GPA) is a systemic necrotizing vasculitis (polyangiitis) with a predilection for the upper and lower respiratory tracts and the kidneys. A "limited" form, with clinical findings isolated to the upper respiratory tract or the lungs, occurs in approximately one-fourth of cases. Essentially all patients with GPA have upper airway or pulmonary involvement. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Microscopic polyangiitis
         </strong>
         – Microscopic polyangiitis (MPA) is a necrotizing vasculitis without granulomatous inflammation that predominantly affects small vessels (ie, capillaries, venules, or arterioles) and can present with pulmonary capillaritis or interstitial lung disease. It causes rhinosinusitis less commonly than GPA. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Airway and lung involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Upper airway involvement
         </strong>
         – The most common presenting symptoms and signs of GPA and MPA in the upper airway include nasal crusting, sinus pain, chronic rhinosinusitis, nasal obstruction, smell disturbances, purulent/bloody nasal discharge, excessive tearing (ie, epiphora), and sinus mucocele formation. Chronic complications include nasal septal perforation, saddle nose deformity, hearing loss, subglottic stenosis, and tracheal collapse. (See
         <a class="local">
          'Nasal, sinus, and ear disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary involvement
         </strong>
         – The clinical manifestations of pulmonary GPA and MPA include cough, hemoptysis (due to alveolar hemorrhage and/or tracheobronchial disease), dyspnea, and less commonly pleuritic pain. The severity of pulmonary involvement is highly variable. (See
         <a class="local">
          'Airway and lung involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory testing
         </strong>
         – More than 90 percent of patients with both lung and kidney involvement have elevated serum antinuclear cytoplasmic antibodies, but the ANCA may sometimes be negative in limited GPA. In GPA, ANCAs are most often directed against serine protease 3 (PR3, or C-ANCA); in MPA, ANCAs are usually directed to MPO. Direct testing for PR3 and MPO antibodies has much higher specificity and positive predictive value than ANCA immunofluorescence testing. (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Granulomatosis with polyangiitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging findings
         </strong>
         – Computed tomography is the preferred imaging modality for characterizing the upper and lower airways in patients with suspected GPA or MPA. Typical sinus findings include mucosal thickening or opacification in the nasal cavity and paranasal sinuses. Common chest findings include multiple pulmonary nodules and patchy or diffuse areas of ground-glass or consolidative opacities. Reticular changes, interlobular septal thickening, honeycombing, bronchiectasis, pleural effusion, and hilar adenopathy are less commonly seen. (See
         <a class="local">
          'Sinus computed tomography'
         </a>
         above and
         <a class="local">
          'Computed tomography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         – The diagnosis of GPA or MPA is established in patients with a compatible clinical presentation based on the following features (see
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Histopathology'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serologic testing (positive ANCA with autoantibodies to serine proteinase 3 or myeloperoxidase)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Histopathologic evidence of necrotizing vasculitis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exclusion of drug-induced vasculitis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – The sequence and pace of the evaluation depends on the pattern of symptoms and acuity of illness. Tissue confirmation of GPA or MPA is highly desirable, even among patients with a compatible clinical presentation and positive serology, due to the potential toxicity of treatment. Choice of biopsy site is individualized based on accessibility of involved tissues and expected patient tolerance of the procedure. A prompt diagnosis allows the initiation of therapy that may be lifesaving and organ-sparing. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of GPA, MPA, diffuse alveolar hemorrhage, and central airway obstruction are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schirmer JH, Wright MN, Vonthein R, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2016; 55:71.
          </a>
         </li>
         <li class="breakAll">
          Specks, U. Pulmonary vasculitis. In: Interstitial Lung Disease, 5th, Schwarz, MI, King, TE Jr (Eds), People's Medical Publishing House, Shelton, CT, USA 2011. p.765.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lally L, Spiera RF. Pulmonary vasculitis. Rheum Dis Clin North Am 2015; 41:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metaxaris G, Prokopakis EP, Karatzanis AD, et al. Otolaryngologic manifestations of small vessel vasculitis. Auris Nasus Larynx 2002; 29:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadowaki T, Yano S, Yamadori I, et al. A case of sinobronchial syndrome complicated with myeloperoxidase antineutrophil cytoplasmic antibody associated vasculitis: review of the literature. Intern Med 2012; 51:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan EJ, Hoffman GS. Pulmonary vasculitis. Clin Chest Med 1998; 19:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimoto T, Sakaguchi M, Deji N, et al. The occurrence of sensorineural hearing loss in a patient with myeloperoxidase-anti-neutrophil cytoplasmic antibody-related microscopic polyangiitis. Rheumatol Int 2007; 27:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okura T, Miyoshi K, Jotoku M, et al. A patient with myeloperoxidase antineutrophil cytoplasmic antibody-positive polyangiitis who developed sensorineural hearing loss and scleritis. Intern Med 2011; 50:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 2009; 119:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald TJ, DeRemee RA. Head and neck involvement in Wegener's granulomatosis (WG). Adv Exp Med Biol 1993; 336:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener's granulomatosis. Otolaryngol Clin North Am 2003; 36:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Progression and management of Wegener's granulomatosis in the head and neck. Laryngoscope 2012; 122:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felicetti M, Cazzador D, Padoan R, et al. Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes. Clin Rheumatol 2018; 37:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polychronopoulos VS, Prakash UB, Golbin JM, et al. Airway involvement in Wegener's granulomatosis. Rheum Dis Clin North Am 2007; 33:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahrami B, Curragh D, McNab AA, et al. Primary Nasocutaneous Fistulae in Granulomatosis With Polyangiitis: A Case Series and Literature Review. Ophthalmic Plast Reconstr Surg 2021; 37:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solans-Laqué R, Bosch-Gil J, Canela M, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Lupus 2008; 17:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Screaton NJ, Sivasothy P, Flower CD, Lockwood CM. Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT. Clin Radiol 1998; 53:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PY, Adil EA, Irace AL, et al. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. Laryngoscope 2017; 127:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horta-Baas G, Hernández-Cabrera MF, Catana R, et al. Subglottic stenosis in granulomatosis with polyangiitis (Wegener's granulomatosis): Report of 4 cases. Reumatol Clin 2016; 12:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Clinical manifestations and treatment of idiopathic and Wegener granulomatosis-associated subglottic stenosis. JAMA Otolaryngol Head Neck Surg 2013; 139:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KS, Kim TS, Fujimoto K, et al. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients. Eur Radiol 2003; 13:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woywodt A, Goebel U. Bronchial stenosis and extensive bronchiectasis due to Wegener's granulomatosis. Nephron 2000; 85:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada H. ANCA: associated lung fibrosis. Semin Respir Crit Care Med 2011; 32:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hervier B, Pagnoux C, Agard C, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009; 68:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin Exp Rheumatol 2020; 38 Suppl 124:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013; 107:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou P, Li Z, Gao L, et al. Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Respiration 2023; 102:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredi A, Cassone G, Izzo R, et al. Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology. Clin Exp Rheumatol 2023; 41:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch X, López-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 1994; 118:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol 2016; 68:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colby, TV. Diffuse pulmonary hemorrhage in Wegener's granulomatosis. Semin Respir Med 1989; 10:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pesci A, Pavone L, Buzio C, Manganelli P. Respiratory system involvement in ANCA-associated systemic vasculitides. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 Suppl 1:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niles JL, Böttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama H, Uchida K, Sim JJ, et al. A case of pulmonary arteritis with stenosis of the main pulmonary arteries with positive myeloperoxidase-antineutrophil cytoplasmic autoantibodies. Respirology 2000; 5:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain P, Ruchin P, Suttie J. Proximal pulmonary artery stenosis: a rare manifestation of granulomatosis with polyangiitis. Lancet 2016; 387:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammad AJ, Mortensen KH, Babar J, et al. Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype. J Rheumatol 2017; 44:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg DM, Weinberger SE, Fulmer JD, et al. Functional correlates of lung involvement in Wegener's granulomatosis. Use of pulmonary function tests in staging and follow-up. Am J Med 1980; 69:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohrmann C, Uhl M, Warnatz K, et al. Sinonasal computed tomography in patients with Wegener's granulomatosis. J Comput Assist Tomogr 2006; 30:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvera S, Vignaux O, Legmann P. [Sinonasal and cerebral imaging findings in Wegener's granulomatosis]. Presse Med 2007; 36:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990; 97:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein AL, Locke WK. Solitary lung lesions in Wegener's granulomatosis. Pathologic findings and clinical significance in 25 cases. Am J Surg Pathol 1995; 19:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ananthakrishnan L, Sharma N, Kanne JP. Wegener's granulomatosis in the chest: high-resolution CT findings. AJR Am J Roentgenol 2009; 192:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell B, Mohan S, Chahal R, et al. Prognostic Significance of Cavitary Lung Nodules in Granulomatosis With Polyangiitis (Wegener's): A Clinical Imaging Study of 225 Patients. Arthritis Care Res (Hoboken) 2018; 70:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamagata M, Ikeda K, Tsushima K, et al. Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients. Arthritis Rheumatol 2016; 68:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feragalli B, Mantini C, Sperandeo M, et al. The lung in systemic vasculitis: radiological patterns and differential diagnosis. Br J Radiol 2016; 89:20150992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990; 142:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KS, Boiselle PM. Update on multidetector computed tomography imaging of the airways. J Thorac Imaging 2010; 25:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997; 10:2738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson G, Klecka M, Roden AC, et al. Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. Respirology 2016; 21:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borner U, Landis BN, Banz Y, et al. Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener's granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 2012; 26:475.
          </a>
         </li>
         <li class="breakAll">
          Yousem SA. Wegener's granulomatosis. In: Thurlbeck's Pathology of the Lung, 3rd, Churg AM, Myers JL, Tazelaar HD, Wright JL (Eds), Thieme, New York 2005. p.371.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguchi S, Fukuda S, Takizawa M. Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis. Auris Nasus Larynx 2001; 28 Suppl:S53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuzuki K, Fukazawa K, Takebayashi H, et al. Difficulty of diagnosing Wegener's granulomatosis in the head and neck region. Auris Nasus Larynx 2009; 36:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi ES, Colby TV. Wegener's granulomatosis. Semin Diagn Pathol 2001; 18:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz A, Damadoğlu E, Aksoy F, et al. A relapsing case of Wegener's granulomatosis presenting as an endobronchial mass. Tuberk Toraks 2006; 54:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mark EJ, Flieder DB, Matsubara O. Treated Wegener's granulomatosis: distinctive pathological findings in the lungs of 20 patients and what they tell us about the natural history of the disease. Hum Pathol 1997; 28:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Lombard CM. The eosinophilic variant of Wegener's granulomatosis. Hum Pathol 1988; 19:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krupsky M, Landau Z, Lifschitz-Mercer B, Resnitzky P. Wegener's granulomatosis with peripheral eosinophilia. Atypical variant of a classic disease. Chest 1993; 104:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis. A clinicopathologic study of 16 cases. Am J Surg Pathol 1996; 20:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsumata Y, Kawaguchi Y, Yamanaka H. Interstitial Lung Disease with ANCA-associated Vasculitis. Clin Med Insights Circ Respir Pulm Med 2015; 9:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 2004; 9:190.
          </a>
         </li>
         <li class="breakAll">
          Specks U. Pulmonary vasculitis. In: Interstitial Lung Disease, 5th, Schwartz MI, King TE Jr (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.765.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachapalli SM, Kiely PD. Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener's granulomatosis. Scand J Rheumatol 2008; 37:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) 2001; 80:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez Alamino R, Espinoza LR. Vasculitis mimics: cocaine-induced midline destructive lesions. Am J Med Sci 2013; 346:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimarchi M, Nicolai P, Lombardi D, et al. Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. Am J Rhinol 2003; 17:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp SA, High WA, Green JJ. Levamisole-induced Wegener's granulomatosis following contaminated cocaine abuse. Skinmed 2012; 10:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelten BM, Post B. IMAGES IN CLINICAL MEDICINE. Midline Destructive Lesions in a Cocaine User. N Engl J Med 2016; 374:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Della-Torre E, Mattoo H, Mahajan VS, et al. IgG4-related midline destructive lesion. Ann Rheum Dis 2014; 73:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catano J, Uzunhan Y, Paule R, et al. Presentation, Diagnosis, and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases. Chest 2022; 161:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. Ren Fail 2009; 31:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalra A, Yokogawa N, Raja H, et al. Hydralazine-induced pulmonary-renal syndrome: a case report. Am J Ther 2012; 19:e136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009; 19:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novikov P, Makarov E, Moiseev S, et al. Venous thromboembolic events in systemic vasculitis. Ann Rheum Dis 2015; 74:e27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faurschou M, Obel N, Baslund B. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2014; 66:1910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berti A, Matteson EL, Crowson CS, et al. Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clin Proc 2018; 93:597.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4330 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1739240" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Wegener granulomatosis: an analysis of 158 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21374588" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297628" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297628" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25836645" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393040" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Otolaryngologic manifestations of small vessel vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22466835" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A case of sinobronchial syndrome complicated with myeloperoxidase antineutrophil cytoplasmic antibody associated vasculitis: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12161090" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Design of the Wegener's Granulomatosis Etanercept Trial (WGET).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9917965" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pulmonary vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366584" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Small-vessel vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16969635" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The occurrence of sensorineural hearing loss in a patient with myeloperoxidase-anti-neutrophil cytoplasmic antibody-related microscopic polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841333" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A patient with myeloperoxidase antineutrophil cytoplasmic antibody-positive polyangiitis who developed sensorineural hearing loss and scleritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19263410" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8296624" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Head and neck involvement in Wegener's granulomatosis (WG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11148709" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14567060" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Head and neck manifestations of Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22674560" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Progression and management of Wegener's granulomatosis in the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29460094" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18037115" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Airway involvement in Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32282641" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Primary Nasocutaneous Fistulae in Granulomatosis With Polyangiitis: A Case Series and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755865" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8843868" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9833783" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27113905" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26718390" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Subglottic stenosis in granulomatosis with polyangiitis (Wegener's granulomatosis): Report of 4 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23329095" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical manifestations and treatment of idiopathic and Wegener granulomatosis-associated subglottic stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12541109" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940755" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bronchial stenosis and extensive bronchiectasis due to Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25500703" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21674417" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : ANCA: associated lung fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18957485" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32324122" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23434037" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36693330" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36200955" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2221646" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7910729" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26713723" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diffuse pulmonary hemorrhage in Wegener's granulomatosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16457016" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Respiratory system involvement in ANCA-associated systemic vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10817800" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Small vessel vasculitis of the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607730" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11192550" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A case of pulmonary arteritis with stenosis of the main pulmonary arteries with positive myeloperoxidase-antineutrophil cytoplasmic autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27302274" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Proximal pulmonary artery stenosis: a rare manifestation of granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28765242" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7416186" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Functional correlates of lung involvement in Wegener's granulomatosis. Use of pulmonary function tests in staging and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365586" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Sinonasal computed tomography in patients with Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17383849" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : [Sinonasal and cerebral imaging findings in Wegener's granulomatosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2323259" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647199" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726364" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Solitary lung lesions in Wegener's granulomatosis. Pathologic findings and clinical significance in 25 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19234263" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Wegener's granulomatosis in the chest: high-resolution CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992397" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prognostic Significance of Cavitary Lung Nodules in Granulomatosis With Polyangiitis (Wegener's): A Clinical Imaging Study of 225 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26474081" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26876879" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The lung in systemic vasculitis: radiological patterns and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2382908" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463531" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Update on multidetector computed tomography imaging of the airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9493653" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Efficacy of transbronchial biopsy in pulmonary vaculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26809449" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23232198" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener's granulomatosis presenting primarily with sinonasal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23232198" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener's granulomatosis presenting primarily with sinonasal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11683344" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18479857" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Difficulty of diagnosing Wegener's granulomatosis in the head and neck region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11296992" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2006712" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7842215" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Tracheobronchial involvement in Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16615019" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A relapsing case of Wegener's granulomatosis presenting as an endobronchial mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9104945" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Treated Wegener's granulomatosis: distinctive pathological findings in the lungs of 20 patients and what they tell us about the natural history of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3378787" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The eosinophilic variant of Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404215" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Wegener's granulomatosis with peripheral eosinophilia. Atypical variant of a classic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8669527" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis. A clinicopathologic study of 16 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26448696" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Interstitial Lung Disease with ANCA-associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15182268" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15182268" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18830903" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704715" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15457464" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23811575" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Vasculitis mimics: cocaine-induced midline destructive lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12693654" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23008947" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Levamisole-induced Wegener's granulomatosis following contaminated cocaine abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962731" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : IMAGES IN CLINICAL MEDICINE. Midline Destructive Lesions in a Cocaine User.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24651619" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : IgG4-related midline destructive lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34324839" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Presentation, Diagnosis, and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18281855" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Drug-induced vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24276086" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19814644" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20724911" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Hydralazine-induced pulmonary-renal syndrome: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19424772" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19015208" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25381230" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Venous thromboembolic events in systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15838068" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25073637" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29588079" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
